Drug Overdose – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Drug Overdose – Pipeline Review, H2 2019’, provides an overview of the Drug Overdose pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Drug Overdose, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Drug Overdose

– The report reviews pipeline therapeutics for Drug Overdose by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Drug Overdose therapeutics and enlists all their major and minor projects

– The report assesses Drug Overdose therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Drug Overdose”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Drug Overdose

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Drug Overdose pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Adamis Pharmaceuticals Corp

Adapt Pharma Ltd

Amphastar Pharmaceuticals Inc

Crossject SA

Fab’entech SA

Icure Pharmaceutical Inc

Insys Therapeutics Inc

iQure Pharma Inc

Klaria Pharma Holding AB

Mucodel Pharma LLC

Opiant Pharmaceuticals Inc

Orexo AB

PledPharma AB

ResQ Pharma Inc

Worphmed Srl”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Drug Overdose Overview

Drug Overdose Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Overdose Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Overdose Companies Involved in Therapeutics Development

Adamis Pharmaceuticals Corp

Adapt Pharma Ltd

Crossject SA

Fab’entech SA

Icure Pharmaceutical Inc

Insys Therapeutics Inc

Klaria Pharma Holding AB

Opiant Pharmaceuticals Inc

Orexo AB

PledPharma AB

Drug Overdose Drug Profiles

Antibody for Drug Overdose, Opioid Addiction and Poisoning Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-003 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-005 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPNT-006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

physostigmine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Alzheimer's Disease and Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Drug Overdose Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug Overdose Dormant Projects

Drug Overdose Discontinued Products

Drug Overdose Product Development Milestones

Featured News & Press Releases

Jul 12, 2018: Aetna Donates Narcan to Wayne County

Jun 26, 2018: Albertsons Companies Offers Increased Access to Naloxone

Jun 25, 2018: Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

May 29, 2018: ADAPT Pharma Launches New Online Platform for NARCAN

May 09, 2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program

Apr 30, 2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability

Apr 26, 2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations

Apr 25, 2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities

Apr 18, 2018: Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Apr 09, 2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies

Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory

Apr 05, 2018: CVS Health Expands Efforts to Educate Patients about Naloxone

Apr 04, 2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia

Mar 19, 2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities

Mar 05, 2018: Adapt Pharma Expands Technical and R&D Teams

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Drug Overdose, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Drug Overdose – Pipeline by Adamis Pharmaceuticals Corp, H2 2019

Drug Overdose – Pipeline by Adapt Pharma Ltd, H2 2019

Drug Overdose – Pipeline by Amphastar Pharmaceuticals Inc, H2 2019

Drug Overdose – Pipeline by Crossject SA, H2 2019

Drug Overdose – Pipeline by Fab’entech SA, H2 2019

Drug Overdose – Pipeline by Icure Pharmaceutical Inc, H2 2019

Drug Overdose – Pipeline by Insys Therapeutics Inc, H2 2019

Drug Overdose – Pipeline by iQure Pharma Inc, H2 2019

Drug Overdose – Pipeline by Klaria Pharma Holding AB, H2 2019

Drug Overdose – Pipeline by Mucodel Pharma LLC, H2 2019

Drug Overdose – Pipeline by Opiant Pharmaceuticals Inc, H2 2019

Drug Overdose – Pipeline by Orexo AB, H2 2019

Drug Overdose – Pipeline by PledPharma AB, H2 2019

Drug Overdose – Pipeline by ResQ Pharma Inc, H2 2019

Drug Overdose – Pipeline by Worphmed Srl, H2 2019

Drug Overdose – Dormant Projects, H2 2019

Drug Overdose – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Drug Overdose, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports